CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)
$39.77 0.02 (0.0503%)
Analysed CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) News Sources
Eli Lilly Obesity Pill Approval And Sleep Deal Reshape Growth Story
05-04-2026
yahoo.com
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
06-04-2026
yahoo.com
Looks Like M&A Week in 3 Different Sectors
08-04-2026
fool.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Best Buy, Bilibili, Constellation Brands, CoreWeave, Nike, Starbucks, T-Mobile, and More
13-04-2026
247wallst.com
Is This $6.3 Billion Deal a Game Changer for Eli Lilly?
16-04-2026
fool.com
Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals
29-04-2026
yahoo.com
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?
03-05-2026
yahoo.com
Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions
06-05-2026
yahoo.com
Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years
08-05-2026
yahoo.com
Lilly Goes on $20 Billion Buying Spree as It Seeks Next Act
27-05-2026
yahoo.com
What is the current price of CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)?
The current price of CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) is $39.77.
CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) absolute price change since previous trading day?
The absolute price change of CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) since the previous trading day is $0.02.
CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) percentage price change since previous trading day?
The percentage price change of CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) since the previous trading day is 0.0503%.
What is the most recent average sentiment score for CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)?
The most recent average sentiment score for CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) is 60 out of 100.
What is the most recent average sentiment for CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)?
The most recent sentiment for CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ) is .
SEC-8K** Filing Available For CENTESSA PHARMACEUTICALS-ADR (CNTA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.